TSTA3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10376(TSTA3 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P10376(TSTA3 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

**Background of TSTA3 Antibody**

TSTA3 (tumor-specific antigen 3), also known as GDP-L-fucose synthase, is a key enzyme involved in protein fucosylation, a post-translational modification critical for cellular processes like cell adhesion, signaling, and immune response. It catalyzes the final step in the synthesis of GDP-L-fucose, a donor substrate for fucosyltransferases. Dysregulated fucosylation is linked to cancer progression, metastasis, and inflammation, making TSTA3 a potential biomarker and therapeutic target.

TSTA3 antibodies are immunological tools designed to detect and quantify TSTA3 expression in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to study TSTA3's role in cancers (e.g., colorectal, liver, breast) and inflammatory diseases. Elevated TSTA3 levels are associated with poor prognosis in certain malignancies, likely due to enhanced fucosylation promoting tumor cell invasion and immune evasion.

Recent studies also explore TSTA3's involvement in modulating cell-matrix interactions and pathogen-host interactions. These antibodies aid in elucidating molecular mechanisms of fucosylation-related pathways and evaluating therapeutic strategies targeting TSTA3 activity. Commercial TSTA3 antibodies are typically validated for specificity, often targeting conserved epitopes across human and model organisms. Continued research aims to clarify its regulatory networks and translational potential in precision medicine.